Tomoi Yusuke, Soga Yoshimitsu, Iida Osamu, Hirano Keisuke, Suzuki Kenji, Kawasaki Daizo, Yamauchi Yasutaka, Miyashita Yusuke, Tazaki Junichi, Nobuyoshi Masakiyo
Department of Cardiology, Kokura Memorial Hospital, 1-1 Asano, Kokurakita-ku, 802-0001, Kitakyushu, Japan,
Cardiovasc Interv Ther. 2013 Oct;28(4):374-82. doi: 10.1007/s12928-013-0188-6. Epub 2013 Jun 12.
To investigate the efficacy of statin treatment after endovascular therapy (EVT) for isolated below-the-knee (BTK) lesions in patients with critical limb ischemia (CLI). From March 2004 to June 2011, 812 patients (984 limbs, 69.0 % male, 71.6 ± 10.0 years old) with CLI underwent successful EVT for de novo isolated BTK lesions at 11 cardiovascular centers in Japan. Of these patients, 169 patients were treated with statins. Successful EVT was defined as direct-line flow to the pedal arch with <30 % residual stenosis. The multicenter data were analyzed retrospectively for outcomes of overall survival, amputation-free survival (AFS), cardiovascular death, limb salvage, freedom from repeat revascularization, and major adverse limb events [MALE: repeat revascularization for the limb or major amputation (defined as above-the-ankle amputation)]. The mean follow-up period was 19.4 ± 17.6 months. Overall survival, AFS and freedom from repeat revascularization at 4 years were significantly higher in patients treated with statins (64.5 vs. 45.9 %, P = 0.004; 64.1 vs. 43.0 %, P = 0.003; and 56.4 vs. 45.4 %, P = 0.03, respectively). However, rates of cardiovascular death, limb salvage, and MALE at 4 years did not differ significantly between the two groups (86.0 vs. 75.2 %, P = 0.11; 87.2 vs. 87.7 %, P = 0.39; and 84.4 vs. 82.9 %, P = 0.64, respectively). After adjusting all outcomes against differences in prespecified baseline variables, there was no significant difference in overall survival, AFS, cardiovascular death, limb salvage, repeat revascularization, and MALE between the groups. In a subgroup of 513 patients who were ambulatory at baseline, statin treatment significantly improved overall survival [hazard ratio (HR) 0.54, 95 % confidential interval (CI) 0.29-0.97, adjusted P = 0.04] and numerically improved AFS (HR 0.63, 95 % CI 0.35-1.07, adjusted P = 0.086). In this subgroup analysis, there was no significant difference in the rates of repeat revascularization, cardiovascular death, limb salvage, and MALE between patients treated with and without statins. In this retrospective study, the statin treatment after successful EVT establishing one straight line for isolated BTK lesions with CLI do not influence overall survival, AFS, and the rates of cardiovascular death, limb salvage, and MALE. However, in ambulatory patients, the statins may improve overall survival and AFS after successful EVT establishing one straight line for isolated BTK lesions.
为研究他汀类药物治疗对严重肢体缺血(CLI)患者膝下(BTK)孤立性病变血管内治疗(EVT)后的疗效。2004年3月至2011年6月,日本11个心血管中心的812例(984条肢体,男性占69.0%,年龄71.6±10.0岁)CLI患者因新发孤立性BTK病变接受了成功的EVT治疗。其中,169例患者接受了他汀类药物治疗。成功的EVT定义为足弓直接血流且残余狭窄<30%。对多中心数据进行回顾性分析,以评估总生存率、无截肢生存率(AFS)、心血管死亡、肢体挽救、免于再次血管重建以及主要不良肢体事件[MALE:肢体再次血管重建或大截肢(定义为踝关节以上截肢)]的结局。平均随访期为19.4±17.6个月。接受他汀类药物治疗的患者4年时的总生存率、AFS和免于再次血管重建率显著更高(分别为64.5%对45.9%,P = 0.004;64.1%对43.0%,P = 0.003;56.4%对45.4%,P = 0.03)。然而,两组4年时的心血管死亡率、肢体挽救率和MALE发生率无显著差异(分别为86.0%对75.2%,P = 0.11;87.2%对87.7%,P = 0.39;84.4%对82.9%,P = 0.64)。在根据预先设定的基线变量差异对所有结局进行调整后,两组在总生存率、AFS、心血管死亡、肢体挽救、再次血管重建和MALE方面无显著差异。在基线时可走动的513例患者亚组中,他汀类药物治疗显著改善了总生存率[风险比(HR)0.54,95%置信区间(CI)0.29 - 0.97,校正P = 0.04],并在数值上改善了AFS(HR 0.63,95%CI 0.35 - 1.07,校正P = 0.086)。在该亚组分析中,接受和未接受他汀类药物治疗的患者在再次血管重建率、心血管死亡率、肢体挽救率和MALE发生率方面无显著差异。在这项回顾性研究中,对于CLI患者成功进行EVT并为孤立性BTK病变建立一条直线后使用他汀类药物治疗,并不影响总生存率、AFS以及心血管死亡率、肢体挽救率和MALE发生率。然而,在可走动的患者中他汀类药物可能会改善为孤立性BTK病变成功进行EVT后的总生存率和AFS。